sparsentan (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

IgA Nephropathy

Pending FDA approval for IgA nephropathy (IgAN); also called Berger disease

Next:

Pharmacology

Mechanism of Action

Dual endothelin angiotensin receptor antagonist (DEARA)

Selectively blocks endothelin 1A and angiotensin II type 1 receptors

Blocking these receptors reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.